First Diabetes Monitoring in Space: Axiom & Burjeel Make History
Axiom Space and Burjeel Holdings have made a groundbreaking discovery in space healthcare. At an event in New York on September 25, they unveiled the results of the 'Suite Ride' study, marking the first deployment of insulin pens and continuous glucose monitoring (CGMs) in orbit.
The research, conducted on the International Space Station (ISS), has shown that common diabetes monitoring tools function reliably in space. This includes insulin pens and CGMs, which can deliver accurate readings and transmit real-time glucose levels to mission control. The study is the first to continuously monitor crew members' glucose levels on the ISS.
This breakthrough paves the way for the first astronaut with diabetes to fly in space. Burjeel Holdings plans to launch this mission in 2024. The findings also have broader implications for remote healthcare on Earth, potentially benefiting underserved areas.
The 'Suite Ride' study, conducted by Axiom Space and Burjeel Holdings, has demonstrated the reliability of diabetes monitoring tools in space. This breakthrough opens new possibilities for astronauts with diabetes and could have broader impacts on remote healthcare on Earth. The first astronaut with diabetes is expected to fly in space in 2024.
Read also:
- Inequalities in colorectal cancer among racial groups: Insights and actions for support
- Liver Cancer Treatment Method: Insights into Function, Potential Sidelines, Efficiency
- Medical professionals at St. Remigius Hospital's rear facilities in Alexian
- Boron's Impact on Bone Health and its Connection with Bey (Title omitted)
